Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception

被引:35
作者
Brady, BM
Walton, M
Hollow, N
Kicman, AT
Baird, DT
Anderson, RA
机构
[1] Univ Edinburgh, Ctr Reprod Biol, MRC, Human Reprod Sci Unit, Edinburgh EH16 4SB, Midlothian, Scotland
[2] Univ Edinburgh, Ctr Reprod Biol, Contracept Dev Network, Edinburgh EH16 4SB, Midlothian, Scotland
[3] Kings Coll London, Drug Control Ctr, London, England
关键词
etonogestrel; male contraception; progestogen; spermatogenesis; testosterone;
D O I
10.1093/humrep/deh491
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: Combined testosterone and progestogen preparations are a promising approach to male hormonal contraception. We investigated the effect of s.c. etonogestrel with depot testosterone on spermatogenesis in normal men over a period of 48 weeks. Methods: Fifteen healthy men received three s.c. 68 mg etonogestrel implants. Testosterone pellets (400 mg) were administered at 12 weekly intervals. Results: Nine men completed 48 weeks of treatment. Four subjects chose to discontinue after 6 months, one man withdrew from the study early for personal reasons and one was withdrawn due to illness. Sperm concentrations of <1x10(6)/ml were achieved in all men by 16 weeks of treatment. All men became azoospermic, although the time to achieve this varied from 8 to 28 weeks. Azoospermia was maintained in eight of the nine men treated for 48 weeks, one subject showing partial recovery from 40 weeks. Testosterone levels remained in the physiological range throughout. Treatment did not result in weight gain, change in body composition or decline in high-density lipoprotein cholesterol concentrations. Conclusions: The combination of three etonogestrel implants with depot testosterone results in rapid and consistent suppression of spermatogenesis. This can be maintained for up to 1 year and may therefore be a suitable approach for a long-acting male hormonal contraceptive.
引用
收藏
页码:2658 / 2667
页数:10
相关论文
共 60 条
[31]   Effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations [J].
Kamischke, A ;
Heuermann, T ;
Krüger, K ;
Von Eckardstein, S ;
Schellschmidt, I ;
Rübig, A ;
Nieschlag, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (02) :530-539
[32]   Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception [J].
Kamischke, A ;
Venherm, S ;
Plöger, D ;
von Eckardstein, S ;
Nieschlag, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (01) :303-309
[33]  
KICMAN AT, 1995, CLIN CHEM, V41, P1617
[34]   Adrenal and gonadal contributions to urinary excretion and plasma concentration of epitestosterone in men - effect of adrenal stimulation and implications for detection of testosterone abuse [J].
Kicman, AT ;
Coutts, SB ;
Cowan, DA ;
Handelsman, DJ ;
Howe, CJ ;
Burring, S ;
Wu, FCW .
CLINICAL ENDOCRINOLOGY, 1999, 50 (05) :661-668
[35]   Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men [J].
Kinniburgh, D ;
Zhu, H ;
Cheng, L ;
Kicman, AT ;
Baird, DT ;
Anderson, RA .
HUMAN REPRODUCTION, 2002, 17 (06) :1490-1501
[36]  
KNUTH UA, 1989, FERTIL STERIL, V51, P1011
[37]   Potential impact of hormonal male contraception: crosscultural implications for development of novel preparations [J].
Martin, CW ;
Anderson, RA ;
Cheng, L ;
Ho, PC ;
van der Spuy, Z ;
Smith, KB ;
Glasier, AF ;
Everington, D ;
Baird, DT .
HUMAN REPRODUCTION, 2000, 15 (03) :637-645
[38]   Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary-testicular axis in normal men [J].
Martin, CW ;
Riley, SC ;
Everington, D ;
Groome, NP ;
Riemersma, RA ;
Baird, DT ;
Anderson, RA .
HUMAN REPRODUCTION, 2000, 15 (07) :1515-1524
[39]   INHIBITION OF TESTOSTERONE CONVERSION TO DIHYDROTESTOSTERONE IN MEN TREATED PERCUTANEOUSLY BY PROGESTERONE [J].
MAUVAISJ.P ;
KUTTENN, F ;
BAUDOT, N .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1974, 38 (01) :142-147
[40]  
MCLACHLAN R, 2002, J CLIN ENDOCR METAB, V87, P46